Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases.

ABSTRACT:

Background

For patients with colorectal cancer liver metastasis (CRCLM), curative-intent liver therapies are associated with improved survival. However, randomized data are lacking, and individual-level retrospective data are limited by selection bias. We aimed to quantify the survival impact of these therapies by analyzing how regional variation in liver therapy rates influence survival outcomes within health service areas (HSA).

Patients and methods

The Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2000-2020) was analyzed for patients aged 66-85 years with liver-isolated CRCLM who underwent curative-intent liver therapy (i.e., hepatectomy, ablation, or transplantation). Rates of resection within HSAs for each year were calculated. A comparison of ob

SUBMITTER: Tsagkalidis V 

PROVIDER: S-EPMC12317857 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature